*PLEASE READ!!*

**HELENA LABORATORIES**

**PROCEDURE DOWNLOAD END USER AGREEMENT**

In response to customer requests, Helena is pleased to provide the text for procedural package inserts in a digital format editable for your use. The text for the procedure you requested begins on page three of this document. Helena procedures contain the content outlined in the NCCLS (GP2-A#) format, except in the order sequence required by FDA regulations. As the NCCLS format is a guideline, you may retain these procedures as developed by the manufacturer (adding your title/authorization page) or manipulate the text file to produce your own document, matching the NCCLS section order exactly, if preferred.

We also provide the procedure in an Adobe Acrobat PDF format for download at www.helena.com as a “MASTER” file copy. Below are the specifications and requirements for using these digital files. Following the specifications is the procedure major heading sequence as given in the FDA style. Where there is a difference in order, or other notation in the outline, this will be indicated in braces { }.

WHAT YOU NEED TO KNOW:

1) These files represent the most current revision level to date. Your current product inventory could contain a previous revision level of this procedure.

2) The Microsoft Word document provides the text only from the master procedure, in a single-column format.

* It may not contain any illustrations, graphics or captions that may be part of the master procedure included in the kit.
* The master procedure may have contained special formatting characters, such as subscripts, superscripts, degree symbols, mean symbols and Greek characters such as alpha, beta, gamma, etc. These symbols may or may not display properly on your desktop.
* The master procedures may also contain columns of tabbed data. Tab settings may or may not be displayed properly on your desktop.

3) The Adobe Acrobat PDF file provides a snapshot of the master procedure in a printable 8.5 x 11” format. It is provided to serve as a reference for accuracy.

4) By downloading this procedure, your institution is assuming responsibility for modification and usage.

**HELENA LABORATORIES**

**PROCEDURE DOWNLOAD END USER AGREEMENT**

HELENA LABORATORIES LABELING – Style/Format Outline

1. PRODUCT {Test} NAME
2. INTENDED USE and TEST TYPE (qualitative or qualitative)
3. SUMMARY AND EXPLANATION
4. PRINCIPLES OF THE PROCEDURE

{*NCCLS lists SAMPLE COLLECTION/HANDLING next}*

1. REAGENTS (name/concentration; warnings/precautions; preparation; storage; environment; Purification/treatment; indications of instability)
2. INSTRUMENTS required – Refer to Operator Manual (... for equipment for; use or function; Installation; Principles of operation; performance; Operating Instructions; Calibration\* {\*is next in order for NCCLS – also listed in “PROCEDURE”}’ precautions/limitations/hazards; Service and maintenance information
3. SAMPLE COLLECTION/HANDLING
4. PROCEDURE

{*NCCLS lists QUALITY CONTROL (QC) next}*

9) RESULTS (calculations, as applicable; etc.)

10) LIMITATIONS/NOTES/INTERFERENCES

11) EXPECTED VALUES

12) PERFORMANCE CHARACTERISTCS

13) BIBLIOGRAPHY (of pertinent references)

14) NAME AND PLACE OF BUSINESS OF MANUFACTURER

15) DATE OF ISSUANCE OF LABELING (instructions)

For Sales, Technical and Order Information, and Service Assistance,   
call Helena Laboratories toll free at 1-800-231-5663.

Form 364

Helena Laboratories

1/2006 (Rev 3)

English

**PLATELETWORKS® ADP and Collagen   
Cat. No. 5860, 5862, 5850, 5852, 5854**



**INTENDED USE**

Plateletworks is an in vitro diagnostic screening assay for the determination of % platelet aggregation or % platelet inhibition in fresh whole blood. The samples may be taken during cardiac interventional procedures or other surgical or treatment settings facing similar risks from thrombosis. Plateletworks may also be used when there are general concerns about the effects of drug therapies on platelet function. The change in platelet count due to activation and aggregation of functional platelets is measured using an electronic impedance-based cell counter.

**SUMMARY**

The anucleate, multifunctional platelet circulates as a cellular component of the blood and provides the first line of defense against bleeding. Subsequent to vasculature injury, platelets adhere to collagen that becomes exposed as a result of endothelial disruption. They then undergo a radical shape change and release adenosine diphosphate (ADP), a physiological agonist which activates additional platelets. Ultimately, a primary hemostatic plug is formed due to the cyclic and self-perpetual stimulation of platelets as they aggregate, release other agonists, and interact with the proteins of the coagulation cascade to form a fibrin clot.

To determine the functionality of primary hemostasis in a given patient, platelets must be assessed in two ways: 1) by measuring the platelet count, and 2) by testing platelet function. If the platelet count is low (generally < 50,000/mL), the ability of the platelets to aggregate properly may be compromised. However, even with a normal platelet count, the platelets may be dysfunctional due to congenital or acquired conditions. If platelets are not aggregating normally, the outcome may be either hemorrhage or unwanted clotting. More specifically, inadequate platelet aggregation may lead to bleeding complications, and platelets that are excessively activated can potentially initiate a thrombotic event such as myocardial infarction, ischemia, stroke, reocclusion following coronary angioplasty, and others.

As a result, it may be desirable to assess platelet count and platelet aggregation or platelet inhibition in certain patient populations. In particular, these include patients undergoing cardiopulmonary bypass, coronary angioplasty, and individuals receiving drug therapies known to affect platelet aggregation. Test results obtained may be useful for pre-and post-surgical determinations for more definitive therapy. Further, platelet aggregation studies performed using multiple agonists may also be helpful in this regard.

**PRINCIPLE**

Traditional platelet aggregometry, the reference method and “gold standard” for testing platelet function, is based on the addition of platelet agonists such as collagen, ADP and others to a blood sample (usually platelet rich plasma). Platelet aggregation may be assessed using these agonists, individually and/or as a panel, as part of the diagnostic intervention into various conditions of congenital and acquired platelet dysfunction. The chart below represents what the different agonist results suggest at baseline.1 It may be beneficial for any abnormal baseline results to be further investigated using additional platelet testing methodologies such as platelet count, bleeding time, assessment of platelet morphology by electron microscopy, measurement of platelet-specific proteins indicative of platelet activation, and others. Such follow-up testing should be conducted in light of patient history, the clinical presentation, and physician discretion.

**Condition Collagen ADP**

Afibrinogenemia N D

Bernard Soulier Syndrome N N

Glanzman’s Thrombasthenia D D

Aspirin Ingestion D D

von Willebrand’s Syndrome N N

Uremia D D

Storage Pool Disease D D

N = Normal, D = Decreased

These agonists serve to stimulate the platelet, and the pattern of aggregation is recorded on a strip chart. The curve is then interpreted by the operator. Unfortunately, the reproducibility of results is dependent on many factors, and the test is highly labor intensive and expensive. For these reasons, platelet aggregometry is not routinely performed in most laboratories. As a result, platelet aggregation testing capabilities have been largely unavailable despite the strong clinical need for this data.

The Plateletworks methodology is an adaptation of platelet aggregometry that is extremely simple, inexpensive, and quick to perform (results are available in about five minutes). This two-step method involves using a cell counter to measure total platelet count in a whole blood sample and then to redetermine the platelet count on a second sample that has been exposed to a known platelet agonist. The agonist will stimulate those platelets which are functional to aggregate into clumps, and they will not be counted as platelets in the second sample. The difference in the platelet count between samples one and two provides a direct measurement of platelet aggregation and is reported as percent aggregation as per the following equation:

**Baseline Platelet Count – Agonist Platelet Count X 100 = % Aggregation**

**Baseline Platelet Count**

Platelets rendered inactive or non-functional by pharmaceutical intervention are considered inhibited. The Plateletworks results may be expressed as percent inhibition instead of percent aggregation.

**Agonist Platelet Count X 100 = % Inhibition**

**Baseline Platelet Count**

Users may refer to the % Aggregation/Inhibition Chart in each box of Plateletworks tubes.

**REAGENTS**

**For In Vitro Diagnostic Use**

Each Plateletworks kit contains baseline tubes and/or agonist tubes depending on the configuration of the kit. The tube contents are as follows:

<EDTA (baseline) tube: 24 µL containing 1.8 mg of K3EDTA (liquid)

<ADP tube (gray top): 10µg ADP (bacterial), 3.2 mg sodium citrate, buffer salts (lyophilized)

<Collagen tube (white top): 10 µg collagen (equin tendon), 3.2 mg sodium citrate (liquid)

<Arachidonic Acid tube (yellow top): 125 µg arachidonic acid, 3.2 mg sodium citrate, buffer salts, bovine serum albumin (lyophilized)

**Note:** All reagents are of non-human origin. Each Plateletworks tube requires a 1.0 cc fresh, human blood sample.

**Storage and Stability**

All Plateletworks tubes should be stored at 2-8°C prior to use. When stored at 2-8°C, the tubes are stable until the marked expiration date. When stored at room temperature (20-24°C), ADP tubes are stable for one month. However, it is not recommended that Collagen tubes be stored at room temperature for longer than one week.

**INSTRUMENT**

The Plateletworks tubes can be run on any hematology analyzer utilizing impedance methodology for determining platelet counts from whole blood. For detailed instructions, refer to the appropriate Operator’s Manual.

**SPECIMEN COLLECTION AND PREPARATION**

Blood samples should be collected via routine method (i.e., indwelling catheter line, venipuncture, etc.). No anticoagulation of the blood is required. Samples should be drawn in a manner to prevent contamination with tissue thromboplastin, indwelling IV solutions, and other interfering substances. Blood collection guidelines are described in the CLSI document GP41-Ed7, April 2017: "Collection of Diagnostic Venous Blood Specimens”.

**Venipuncture**

When using a venipuncture technique, needles of 19 to 22 gauge should be used to reduce the potential for platelet activation during specimen collection. For pediatric patients, a 21 to 23 gauge needle may be used. Withdraw 2.0 cc of blood and discard it. Then collect a 2.5 cc sample of fresh whole blood for testing (1.0 cc for baseline tube and 1.0 cc for agonist tube).

**Extracorporeal Line**

Using a two-syringe technique, flush the extracorporeal blood access line by withdrawing 2.0 cc of blood into a syringe and discarding it. Then use a second syringe to obtain a 2.5 cc sample of fresh whole blood for testing (1.0 cc for baseline tube and 1.0 cc for agonist tube).

**Indwelling Catheter Line**

Discontinue fluids drip, if necessary, and flush the line with 5 mL saline. Using a two-syringe technique, withdraw 2.0 cc of blood into a syringe and discard it. Then use a second syringe to obtain a 2.5 cc sample of fresh whole blood for testing (1.0 cc for baseline tube and 1.0 cc for agonist tube).

**NOTE:** The appropriate amount of blood from the hypodermic needle/syringe must be added to the EDTA and agonist tubes within one minute after completion of the draw. The agonist tube should be tested within ten minutes after sample addition to the tube.

**PROCEDURE**

**Materials Provided**

The Plateletworks Kits include agonist tubes, baseline tubes and a % Aggregation/Inhibition chart. A Plateletworks Aggregation/Inhibition Calculation Wheel (584) is also available upon request.

**Contents Cat. No.**

Plateletworks Collagen Kit 5862

25 Collagen tubes

25 Baseline (EDTA) tubes

Plateletworks ADP Kit 5860

25 ADP tubes

25 Baseline (EDTA) tubes

Plateletworks Combo-15 Kit 5850

15 Collagen Tubes

15 ADP Tubes

15 Baseline (EDTA) Tubes

Plateletworks Combo-25 Kit 5852

25 Collagen Tubes

25 ADP Tubes

Plateletworks Combo-10 Kit 5854

10 Collagen Tubes

10 ADP Tubes

10 Arachidonic Acid Tubes

10 Baseline (EDTA) Tubes

**Materials Required but Not Provided**

Impedance cell counter

Blood collection materials (syringes, blood collection set, etc.)

**Step-by-Step Method**

**Note:** If kept refrigerated at 2-8°C, allow Plateletworks tubes to equilibrate to room temperature (20-24°C) before adding sample.

1. Obtain the desired fresh whole blood sample. A 1.0 cc whole blood sample is required for each agonist tube and each baseline tube.

2. Immediately dispense 1.0 cc of blood into each of the baseline tube and the agonist tube.

3. Mix each tube (baseline and agonist) vigorously 15 to 20 times to ensure adequate mixing.

4. The baseline tube is then run on an appropriate cell counter, recording the platelet count.

5. Mix the ADP tube an additional 3 to 5 times and run on the cell counter. Record the platelet count.

6. The Collagen tube is mixed 4-5 times each minute for 4 minutes.

7. The Collagen tube is then run on a cell counter, recording the platelet count.

8. The percent platelet aggregation is then calculated

a) from the % Aggregation/Inhibition Chart supplied in the package of tubes.

b) using the Plateletworks Calculation Wheel.

c) calculated by the appropriate formula.

**Quality Control**

Quality control testing of the cell counter used to perform the Plateletworks assay should be completed during each shift the system is used. These results will ensure that the instrument is functioning properly.

It is suggested that each laboratory establish its own normal range. No commercial controls for platelet aggregation testing are available. Blood drawn from healthy adults may be used as normal controls for the Plateletworks assay. These individuals must be free from any medication known to affect platelet function for a minimum of 5 days and should have prior platelet aggregation tests that fall within the normal range established by the laboratory. If the second normal control value is also outside the normal reference interval, the assay should be considered out of control and no testing should be performed. In this case, contact Helena’s Technical Support for assistance (1-800-231-5663, ext. 600).

**LIMITATIONS**

< Only fresh, human whole blood should be added to the Plateletworks tubes. Do not collect samples into blood collection tubes containing anticoagulant (i.e., sodium citrate, EDTA, or heparin) prior to addition to the Plateletworks tubes.

< It is recognized that many drugs and compounds (prescription and non-prescription) may affect platelet aggregation. The most common of these is aspirin. Therefore, a complete medical history that includes a list of drugs taken for 7-10 days prior to testing should be obtained.

< The validity of the Plateletworks assay is dependent on the accuracy of the platelet counts obtained. Multiple factors may potentially interfere with the accuracy of the platelet count when performed on an automated cell counter. Therefore, platelet counts obtained should be scrutinized in light of the patient’s clinical circumstance and previous platelet count results. Plateletworks results should always be interpreted in light of the clinical history and condition of the patient.

< The agonist tube should be tested within **ten minutes** after sample addition to the tube.

< It may be beneficial for any abnormal baseline results to be further investigated using additional platelet testing methodology, such as platelet count, bleeding time, assessment of platelet morphology, and others.

<Do not use Plateletworks tubes past their expiration date or those which have been improperly stored.

< Plateletworks results may be affected by poor technique (e.g., improper blood sample volume, delayed test performance beyond recommended procedure, etc.).

**INTERFERENCES**

<Pseudothrombocytopenia, though infrequent, can result from EDTA-dependent platelet agglutination. Pseudothrombocytopenia may be suspected with the Plateletworks assay if the platelet count determined using the agonist tube is higher than the platelet count determined using the baseline tube (containing EDTA anticoagulant). If pseudothrombocytopenia is suspected, common laboratory practice is to re-draw the blood sample into a sodium citrate collection tube and perform the blood count; the results should be corrected by a factor of 1.1 to account for the sample dilution that occurs with the use of sodium citrate as an anticoagulant. This procedure should be followed using the sodium citrate tube in lieu of the Plateletworks baseline tube, followed by the Plateletworks agonist tube, to determine percent platelet aggregation.

< Cell counters utilizing electronic impedance cell counting principles may be subject to known interfering substances which can impact platelet count results. These include:

< Microcytes, schizocytes, and WBC fragments, which may interfere with the proper counting of platelets and cause elevated platelet counts

< Agglutinated erythrocytes, which may trap platelets and cause an erroneously low platelet count

< Giant platelets, which may cause an erroneously low platelet count since they may exceed the upper limit threshold for the platelet parameter

< Chemotherapy, which may increase the fragility of platelets and cause low platelet counts

< Hemolysis, which contains red cell stroma and may elevate platelet counts

< Acid-citrate-dextrose (ACD) blood, which may contain platelet aggregates that could depress the platelet count

< RBC inclusions, which may produce a spuriously increased platelet count

< Platelet agglutination, due to poor collection techniques or EDTA activation, which may cause a decreased platelet count

**REFERENCE VALUES**

The reference value for each Plateletworks agonist tube was determined on samples collected from healthy volunteers. Each laboratory should establish their own reference range with their normal patient population.13 The data are as follows:

**Agonist Reference Range**

Collagen 70-100%

ADP 86-100%

**PERFORMANCE CHARACTERISTICS**

**Correlation Study**

Correlation of the Plateletworks assay to platelet aggregometry on platelet rich plasma (PRP) is supported by data generated by testing male and female adults, between the ages of 18 and 85, at three clinical sites. This includes normal, healthy volunteers, patients undergoing cardiopulmonary bypass surgery, and patients undergoing cardiac catherization.

All blood samples were acquired from in-dwelling lines or venipuncture using established methods. For the Plateletworks assays and PRP aggregometry, the manufacturers’ recommendations were adhered to as per instructions provided in the package insert.

Regression analysis (correlation coefficients) was performed to assess the agreement between the two methods. A positive correlation was demonstrated for each agonist. See Figures 1 and 2.




Figure 1: ADP



Figure 2: Collagen

However, it is recognized that correlation coefficients measure the strength of the relationship between the methods and not the agreement between them.2 Further, since the aggregation system is bounded by 100% as the upper limit of aggregation regression analysis is not expected to describe a predictive relationship. Therefore, the data from the clinical sites where substantial equivalence testing was performed were also subjected to the non-parametric analysis of Spearman Rho which “tests for a positive correlation without specifying linearity”. The results from these analyses are shown (with the regression analysis).

**Comparative Data: Plateletworks vs PRP Aggregometry**

N (Pearson)r Spearman Rho

ADP 225 0.83\* 0.68\*

\*P < 0.001 two-sided test of positive association significant

**Comparative Data: Liquid Collagen vs Lyophilized Collagen**

N (Pearson)r Spearman Rho

Collagen 154 0.89\* 0.88\*

\*P < 0.001 two-sided test of positive association significant

**Note:** Thrombocytopenic samples may be tested using the Plateletworks assay. As this system utilizes electrical impedance cell counting principles (i.e., Ichor II Analyzer), instrument platelet counts > 10 x 103/mL can be accurately obtained. Agonist platelet counts can be measured in samples meeting the limits of aggregation detection (> 27 x 103/mL). Although EDTA-induced thrombocytopenic samples may be tested using the Plateletworks assay, no actual testing was performed on this sample type.

**Precision**

Precision of the Plateletworks assay was determined in two ways. First, a sample from a single healthy volunteer was tested on each of ten days with the agonist. (Although the samples were drawn from the same individual, some differences are to be expected due to diurnal physiological variation.) The coefficients of variation was 5.1% for ADP and 5.9% for Collagen.

Additionally, 10 sample aliquots from a single healthy volunteer were tested during a 20 minute interval with the agonist. The coefficients of variation was 4.1% for ADP and 4.9% for Collagen.

This data supports the reproducibility of the Plateletworks assay. Thus, duplicate testing on a routine basis is not required. Nonetheless, any questionable test result should be repeated, and performed in duplicate.

**BIBLIOGRAPHY**

**Bibliografia/Bibliographie/Bibliografia/Literatur**

1. Triplett DA et al: Platelet function, laboratory evaluation and clinical application. ASCP, Chicago, 1978.

2. Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; Feb: 307-310.

**REFERENCES**

**References/Verveise/Riferimenti/Referencias**

1. Badimon L, Badimon JJ, Fuster V: Pathogenesis of thrombosis. In Fuster V, Verstraete M, eds. Thrombosis in cardiovascular disorders. Philadelphia, PA: WB Saunders 1992; 17-39.

2. Born, GVR: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194:927.

3. Califf RA, Willerson JT: Percutaneous transluminal coronary angioplasty: prevention of occlusion and restenosis. In: Fuster V, Verstraete M, eds. Thrombosis in cardiovascular disorders. Philadelphia, PA: WB Saunders 1992; 389-408.

4. Cheeseman JE, Mills SP, Hardisty RM: Platelet aggregometry on whole blood: the use of the ELT8/ds blood cell counter in the investigation of bleeding disorders. Clin Lab Haemat 1984; 6:265-272.

5. Despotis GJ, Levine VL, Goodnough LT. Relationship between leucocyte count and patient risk for excessive blood loss after cardiac surgery. Crit Care Med. 1997; 25:1338-1346.

6. Gasperti CM, Gonias ST, Gimple LW, et al: Platelet activation during coronary angioplasty in humans. Circulation 1993; 88:2728-2734.

7. Harker LA, Mann KG: Thrombosis and Fibrinolysis. In: Fuster V, Verstraete M, eds. Thrombosis in cardiovascular disorders. Philadelphia, PA: WB Saunders 1992; 1-16.

8. Ingerman-Wojenski CM, Silver MJ: A quick method for screening platelet dysfunctions using the whole blood lumi-aggregometer. Thromb Hemo 1984; 51(2):154-156.

9. Marcus AJ, Safier LB: Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB 1993;7:516-522.

10. Sughayer M, Arkin CF: Monitoring coagulation during and after cardiopulmonary bypass surgery. Thromb Hemost. 1990; 12(4):1-7.

11. Schror K: Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Sem Throm Hemost 1997; 23(4):349-356.

12. Weiss HJ, Rogers J: Thrombocytopenia due to abnormalities in platelet release reaction. Blood 1972;39:2.

13. Clinical and Laboratory Standards Institute. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline. CLSI Document EP28-A3c, Vol. 28, No. 30, October 2010.

For Sales, Technical and Order Information and Service Assistance, call 800-231-5663 toll free.

Helena Laboratories warrants its products to meet our published specifications and to be free from defects in materials and workmanship. Helena’s liability under this contract or otherwise shall be limited to replacement or refund of any amount not to exceed the purchase price attributable to the goods as to which such claim is made. These alternatives shall be buyer’s exclusive remedies.

In no case will Helena Laboratories be liable for consequential damages even if Helena has been advised as to the possibility of such damages.

The foregoing warranties are in lieu of all warranties expressed or implied including, but not limited to, the implied warranties of merchantability and fitness for a particular purpose.

© 2023

 Helena Laboratories, Corp.

1530 Lindbergh Drive

Beaumont, TX 77707 USA

Pro 190

12/22(11)

